Drug-resistant tuberculosis medical therapy
Tuberculosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Drug-resistant tuberculosis medical therapy On the Web |
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy |
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Multiple Drug-Resistant (MDR) Tuberculosis
- MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
- Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
- Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.
- Chronic cases with severe pulmonary disease may require more than 24 months of therapy.
MDR Tuberculosis ▸ Adults ▸ Children |
|
Extensively Drug-Resistant XDR Tuberculosis
XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).
XDR Tuberculosis ▸ Adults ▸ Children |
|
Extremely Drug-Resistant (XXDR) Tuberculosis
References
- ↑ http://www.who.int/tb/publications/tb_treatmentguidelines/en/. Unknown parameter
|Title=
ignored (|title=
suggested) (help); Missing or empty|title=
(help)